BioNTech reports Q3 results, reconfirms FY guidance

  • BioNTech press release (NASDAQ:BNTX): Q3 GAAP EPS of €0.81
  • Revenue of €1.2B (+34.0% Y/Y).
  • Expects to be at low end of full year 2024 revenue guidance range (€2.5-3.1 billion)
  • Re-confirms guidance of planned full year 2024 R&D expenses of €2.4-2.6 billion

Leave a Reply

Your email address will not be published. Required fields are marked *